QUE Oncology

QUE Oncology is a clinical-stage company dedicated to developing drugs that address significant medical needs. The company's lead drug program, Q-122, focuses on the treatment of hot flashes in breast cancer patients and survivors undergoing endocrine therapy. Multiple clinical studies of Q-122 have shown that the drug can be safely administered to over 60 patients and healthy volunteers. QUE Oncology recently completed enrollment for a double-blind, placebo-controlled Phase 2 study targeting breast cancer patients and survivors.